Kaspofungin Ligula Pharma

Caspofungin, the active ingredient in Kaspofungin Ligula Pharma, is an echinocandin presented as an intravenous formulation for systemic use. It is employed to treat invasive candidiasis, candidemia, esophageal candidiasis, and intra‑abdominal abscesses caused by susceptible Candida species in adult patients.

GNH USA supplies Kaspofungin Ligula Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution efficiently and timely.

Caspofungin is an echinocandin antifungal used to treat invasive Candida infections. - Invasive candidiasis: effective in clearing bloodstream and deep tissue Candida infections. - Candidemia: eradicates Candida species from the bloodstream. - Esophageal candidiasis: resolves mucosal infection of the esophagus. - Intra‑abdominal abscesses caused by susceptible Candida species: aids in infection control and abscess resolution.

Caspofungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Chills: shaking sensation often accompanying infusion. - Nausea: mild gastrointestinal discomfort. - Elevated liver enzymes: transient increase in ALT/AST. - Headache: mild to moderate intensity. - Rash: non‑specific skin eruption.

Serious or Rare Side Effects: - Hypotension: significant drop in blood pressure during infusion. - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Hepatotoxicity: marked elevation of liver transaminases or bilirubin. - Severe infusion reactions: bronchospasm or dyspnea. - Renal impairment: acute kidney injury in susceptible patients.

Caspofungin should be used with caution, observing specific clinical and handling precautions. - Renal function: assess baseline renal function and monitor during therapy. - Hepatic function: evaluate liver enzymes prior to initiation and periodically thereafter. - Concomitant medications: review for potential interactions, especially with cytochrome P450 substrates. - Infusion rate: administer intravenously over the recommended period to reduce infusion‑related reactions. - Pregnancy and lactation: consider risk‑benefit ratio; use only if clearly needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Caspofungin can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Cytochrome P450 inducers: may reduce caspofungin exposure (e.g., rifampin, carbamazepine). - Strong CYP3A4 inhibitors: may increase exposure, requiring dose adjustment (e.g., ketoconazole).

Moderate Interactions (Monitor Closely): - Azole antifungals: concurrent use may affect plasma levels. - Immunosuppressants: monitor levels of tacrolimus or cyclosporine. - Warfarin: observe INR for potential changes. - Statins metabolized by CYP3A4: watch for increased statin concentrations.